GFM
VYGR icon

GF Fund Management’s Voyager Therapeutics VYGR Stock Holding History

GF Fund Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36K Sell
1,245
-94
-7% -$356 ﹤0.01% 575
2026
Q1 		$5.17K Buy
1,339
+161
+14% +$634 ﹤0.01% 605
2025
Q4 		$4.63K Sell
1,178
-15
-1% -$66 ﹤0.01% 624
2025
Q3 		$5.57K Sell
1,193
-162
-12% -$586 ﹤0.01% 604
2025
Q2 		$4.21K Hold
1,355
– – ﹤0.01% 636
2025
Q1 		$4.58K Buy
1,355
+208
+18% +$972 ﹤0.01% 628
2024
Q4 		$6.5K Buy
+1,147
New +$7.39K ﹤0.01% 598

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GF Fund Management's VYGR Position: Q2 2026 in Review

GF Fund Management reduced its Voyager Therapeutics (VYGR) stake by 7% in Q2 2026, selling an estimated $356 and leaving 1,245 shares worth $4.36K. The position accounts for ﹤0.01% of the portfolio, ranked #575.

GF Fund Management first reported a position in VYGR in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.5K in Q4 2024. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • GF Fund Management held 1,245 shares of Voyager Therapeutics worth $4.36K as of Q2 2026.
  • GF Fund Management sold 94 Voyager Therapeutics shares in Q2 2026, an estimated $356.
  • Voyager Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #575 holding.
  • GF Fund Management first reported a position in Voyager Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Voyager Therapeutics position peaked at $6.5K in Q4 2024.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.